Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Altabás-González, Irene
- dc.contributor.author Salman-Monte, Tarek Carlos
- dc.contributor.author Rúa-Figueroa, Iñigo
- dc.date.accessioned 2025-07-16T07:33:54Z
- dc.date.available 2025-07-16T07:33:54Z
- dc.date.issued 2025
- dc.description.abstract Objectives: To provide an overview on the current use of belimumab (BLM) in SLE patients in clinical practice and to examine its efficacy in terms of standardized outcomes, drug survival, as well as patient and safety profiles. Methods: A longitudinal retrospective multicenter cohort including SLE patients treated with BLM at 18 Spanish centers. Data was collected upon initiation of BLM, at 6 and 12 months after initiation, and at the last recorded visit. Changes in SLEDAI-2K, the proportion of patients who achieved LLDAS and DORIS 2021, and number of flares were compared between visits. Changes in damage, glucocorticoids use and employment status pre-BLM and post-BLM were also assessed. Results: A total of 324 patients were included with a mean follow-up of 3.8 (±2.7) years. LLDAS was attained by 45.8%, 62% and 71% of patients, and DORIS by 24%, 36.2% and 52.5% on successive visits, respectively. A total of 27.2% of patients were in DORIS ≥50% of the visits and 46% in LLDAS-50. Flares and number of flares were significantly lower one year after treatment with BLM and no changes in damage accrual were observed. Mean (±SD) prednisone dose was significantly reduced over time, with 70 (24%) patients discontinuing GC. Conclusion: Our study not only demonstrates belimumab's efficacy in attaining treat-to-target goals in SLE patients, but also confirms its GC-sparing effect, and its prevention of flares and organ damage accrual.
- dc.format.mimetype application/pdf
- dc.identifier.citation Altabás-González I, Pego-Reigosa JM, Mouriño C, Jiménez N, Hernández-Martín A, Casafont-Solé I, et al. Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients. Rheumatology (Oxford). 2025 Jan 1;64(1):276-82. DOI: 10.1093/rheumatology/kead696
- dc.identifier.doi http://dx.doi.org/10.1093/rheumatology/kead696
- dc.identifier.issn 1462-0324
- dc.identifier.uri http://hdl.handle.net/10230/70928
- dc.language.iso eng
- dc.publisher Oxford University Press
- dc.relation.ispartof Rheumatology (Oxford). 2025 Jan 1;64(1):276-82
- dc.rights © The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
- dc.subject.keyword DORIS
- dc.subject.keyword LLDAS
- dc.subject.keyword Spanish
- dc.subject.keyword Belimumab
- dc.subject.keyword Biologics
- dc.subject.keyword Cohort
- dc.subject.keyword Effectiveness
- dc.subject.keyword Remission
- dc.subject.keyword Systemic lupus erythematosus
- dc.subject.keyword Target
- dc.title Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion